LANCER

Study at a Glance

Estimated Time Commitment

To be discussed

Eligibility

Ordinal 5, hospitalized within last 48 hours

Diagnosis Required

Confirmed COVID diagnosis

Diseases Being Studied

SARS-CoV-2
Location: San Antonio, TX

Sponsor: CardiolTherapeutics

Coordinating Center/CRO: Worldwide Clinical Trials

Primary Objective: To evaluate the safety of CardiolRx™in patients with COVID-19 infection

Study drugs: CBD vs placebo

Sample size: 422

Start up status: Has been submitted to WIRB, Institutional approvals in progress

Meet Your Clinical Research Team

Contact us

Principal Investigator: All Infectious Diseases Faculty, Dr. John Erikson MD, and Dr. Sachin Saboo MD

For more information please contact Dr. Barbara Taylor